Lista de obras -

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

artículo científico publicado en 2017

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

artículo científico publicado en 2016

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium

artículo científico publicado en 2009

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium

artículo científico

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

artículo científico

Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials

artículo científico publicado en 2008

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

artículo científico publicado en 2015

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

artículo científico publicado en 2016

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer

artículo científico publicado en 2008

Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress

artículo científico publicado en 2009

Cooperative group research endeavors in small-cell lung cancer: current and future directions

artículo científico publicado en 2009

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer

artículo científico publicado en 2014

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung

artículo científico publicado en 2016

Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer

artículo científico publicado en 2015

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

artículo científico publicado en 2017

Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial

artículo científico publicado en 2012

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer

artículo científico publicado en 2016

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

artículo científico publicado en 2013

Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents

artículo científico publicado en 2014

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer

artículo científico publicado en 2014

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

artículo científico publicado en 2016

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies

scientific article published on 04 December 2018

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

artículo científico publicado en 2016

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

artículo científico publicado en 2016

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer

scientific article published on August 2011

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

artículo científico publicado en 2008

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer

artículo científico publicado en 2017

Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

artículo científico publicado en 2010

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

artículo científico publicado en 2015

Probability of cancer in pulmonary nodules detected on first screening CT.

artículo científico publicado en 2013

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

artículo científico publicado en 2009

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

artículo científico publicado en 2009

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

artículo científico publicado en 2009

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada

artículo científico publicado en 2014

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer

artículo científico

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

artículo científico publicado en 2016

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway

artículo científico publicado en 2006

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

artículo científico

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.

artículo científico publicado en 2017

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

artículo científico publicado en 2009

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future

artículo científico publicado en 2014

Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de marzo de 2012

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

scientific article published on December 2008

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

artículo científico publicado en 2005

Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.

artículo científico publicado en 2017

miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma

artículo científico publicado en 2015

Lista de obras de

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer

Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress

Cooperative group research endeavors in small-cell lung cancer: current and future directions

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung

Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer

Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Probability of cancer in pulmonary nodules detected on first screening CT.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future

Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer ⬇️

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.

miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma